How should a sponsor audit a provider's tech-transfer record before signing?

Request completed transfer counts by modality, average time from kickoff to engineering run, and deviation rates on first GMP batches. Ask for two reference sponsors at a comparable stage. Providers in the Advanced Therapy Medicinal Products CDMO Market that decline these metrics usually lack them [9]. Read More

What contract structures are typical for reserved capacity?

Suite reservation agreements combine a monthly holding fee with committed minimum batch counts, usually over three to five years. Take-or-pay clauses are standard in the Advanced Therapy Medicinal Products CDMO Market. Negotiate release windows for programme discontinuation [4]. Read More

Is dual-sourcing worth the cost in the Advanced Therapy Medicinal Products CDMO Market?

For commercial products, yes — regulators increasingly expect supply-continuity plans. Expect USD 8–15 Million and 18 months to qualify a second site. Clinical-stage programmes rarely justify it [10]. Read More

How do potency-assay requirements affect vendor selection?

Providers must own validated, product-specific potency methods, not generic surrogates. EMA's 2024 guidance tightened this considerably. Prioritise partners with in-house bioassay development rather than those outsourcing analytics to third parties [13]. Read More

What integration challenges arise when moving work into the Advanced Therapy Medicinal Products CDMO Market from an academic site?

Academic processes typically use open manipulations and non-GMP reagents. Closing the process and re-sourcing materials adds six to twelve months. Budget for full comparability studies against clinical data already generated [17]. Read More

Do non-viral platforms reduce dependence on specialist vendors?

Partially. Transposon and electroporation approaches remove vector supply risk but introduce plasmid quality and electroporation-parameter validation demands. The Advanced Therapy Medicinal Products CDMO Market is adapting, though few providers yet offer end-to-end non-viral capability [3]. Read More

What cross-border regulatory nuance most often delays supply?

Import licensing for human-derived starting material differs sharply by jurisdiction, and cryogenic chain-of-identity documentation is scrutinised at customs. Build 60–90 days of buffer into first-shipment timelines for any new receiving country [13]. Read More

Advanced Therapy Medicinal Products Cdmo Market (2026 - 2035)

Advanced Therapy Medicinal Products CDMO Market Research Report By Product Type (Gene Therapy, Cell Therapy, Tissue Engineering), By Indication (Cancer, Immune Disorders, Cardiovascular Diseases, Neurological Disorders), By Scale of Production (Clinical Trial, Commercial Production), By Service Type (Process Development, Manufacturing, Regulatory Support) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2026-2035

CAGR

22.6%

2025 Market Size

USD 6.98 Billion

2035 Market Size

USD 54.03 Billion

Healthcare ● Updated August 2026 Report ID: MRFR/HC/29380-HCR | Pages: 128 | Author: Rahul Gotadki, Satyendra Maurya

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Summary |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Key Report Takeaways |
1. 2.1 By Therapy Type |
2. 2.2 By Service Type |
3. 2.3 By Geography
3 Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2025) |
2. 3.2 Current & Forecast Market Size (2026–2035) |
3. 3.3 Market Size by Revenue (USD Billion) |
4. 3.4 Year-over-Year Growth Analysis
4 Driver Impact Analysis |
1. 4.1 Regulatory Throughput as Demand Engine |
2. 4.2 Sponsor Migration to Outsourced Capacity |
3. 4.3 Vector Capacity Normalisation |
4. 4.4 Automation and Closed Processing
5 Restraints Impact Analysis |
1. 5.1 Cost of Goods and Pricing Pressure |
2. 5.2 Specialist Talent Scarcity |
3. 5.3 Suite Utilisation Gaps
6 Opportunities |
1. 6.1 Allogeneic Platform Economics |
2. 6.2 Non-Viral Delivery Expansion |
3. 6.3 Emerging-Market Capacity Arbitrage |
4. 6.4 Platform and Data Licensing Models |
5. 6.5 Decentralised Point-of-Care Manufacturing
7 Regional Market Share & Country-Level Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of MEA
8 Future Outlook (2026–2035) |
1. 8.1 Machine Learning in Process Control |
2. 8.2 Platform Economics and Standardisation |
3. 8.3 Regulatory Convergence |
4. 8.4 Sustainability in Sourcing Decisions
9 Market Segmentation Analysis |
1. 9.1 By Therapy Type | |
  1. 9.1.1 Cell Therapy | |
  2. 9.1.2 Gene Therapy | |
  3. 9.1.3 Tissue-Engineered Products |
2. 9.2 By Service Type | |
  1. 9.2.1 Process Development | |
  2. 9.2.2 cGMP Manufacturing | |
  3. 9.2.3 Analytical & Testing | |
  4. 9.2.4 Fill-Finish | |
  5. 9.2.5 Regulatory & QA Support |
3. 9.3 By Development Phase | |
  1. 9.3.1 Pre-Clinical | |
  2. 9.3.2 Phase I/II | |
  3. 9.3.3 Phase III | |
  4. 9.3.4 Commercial |
4. 9.4 By Vector Type | |
  1. 9.4.1 AAV | |
  2. 9.4.2 Lentiviral | |
  3. 9.4.3 Adenoviral | |
  4. 9.4.4 Retroviral | |
  5. 9.4.5 Non-Viral / Other |
5. 9.5 By Cell Source | |
  1. 9.5.1 Autologous | |
  2. 9.5.2 Allogeneic
10 Competitive Landscape |
1. 10.1 Market Concentration Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 Lonza | |
  2. 10.3.2 Thermo Fisher Scientific | |
  3. 10.3.3 Catalent | |
  4. 10.3.4 WuXi Advanced Therapies | |
  5. 10.3.5 Charles River Laboratories | |
  6. 10.3.6 Samsung Biologics | |
  7. 10.3.7 Fujifilm Diosynth Biotechnologies | |
  8. 10.3.8 Merck KGaA | |
  9. 10.3.9 Oxford Biomedica | |
  10. 10.3.10 Andelyn Biosciences | |
  11. 10.3.11 Center for Breakthrough Medicines | |
  12. 10.3.12 Nikon CeLL Innovation
11 Recent News & Developments
12 Report Scope & Methodology
13 Detailed Sources & Citations
14 Frequently Asked Questions
15 LIST OF TABLES |
TABLE 1 Global ATMP CDMO Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global ATMP CDMO Market – Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis Matrix, 2026–2035 |
TABLE 4 Restraint Impact Analysis Matrix, 2026–2035 |
TABLE 5 Global ATMP CDMO Market Size, by Therapy Type, 2021–2035 (USD Billion) |
TABLE 6 Global ATMP CDMO Market Size, by Service Type, 2021–2035 (USD Billion) |
TABLE 7 Global ATMP CDMO Market Size, by Development Phase, 2021–2035 (USD Billion) |
TABLE 8 Global ATMP CDMO Market Size, by Vector Type, 2021–2035 (USD Billion) |
TABLE 9 Global ATMP CDMO Market Size, by Cell Source, 2021–2035 (USD Billion) |
TABLE 10 Global ATMP CDMO Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 11 North America ATMP CDMO Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 12 Europe ATMP CDMO Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 13 Asia-Pacific ATMP CDMO Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 14 South America ATMP CDMO Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 15 Middle East & Africa ATMP CDMO Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 16 North America ATMP CDMO Market Size, by Therapy Type, 2021–2035 (USD Billion) |
TABLE 17 Europe ATMP CDMO Market Size, by Service Type, 2021–2035 (USD Billion) |
TABLE 18 Asia-Pacific ATMP CDMO Market Size, by Vector Type, 2021–2035 (USD Billion) |
TABLE 19 Competitive Benchmarking Matrix, 2026 |
TABLE 20 Company Profiles – Key Players |
TABLE 21 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 22 Report Scope & Methodology Summary |
TABLE 23 Detailed Sources & Citations Index
16 LIST OF FIGURES |
FIGURE 1 Market Dynamics – Drivers, Restraints, Opportunities and Challenges |
FIGURE 2 Industry Value Chain Analysis |
FIGURE 3 Porter's Five Forces Analysis |
FIGURE 4 Global Market Size Trend & Forecast, 2021–2035 (USD Billion) |
FIGURE 5 Year-over-Year Growth Trajectory, 2022–2035 (%) |
FIGURE 6 Revenue Share by Therapy Type, 2025 vs 2035 (%) |
FIGURE 7 Revenue Share by Service Type, 2025 (%) |
FIGURE 8 Revenue Share by Development Phase, 2025 (%) |
FIGURE 9 Revenue Share by Vector Type, 2025 (%) |
FIGURE 10 Autologous vs Allogeneic Split, 2025 vs 2035 (%) |
FIGURE 11 Regional Revenue Share, 2025 (%) |
FIGURE 12 Regional CAGR Comparison, 2026–2035 (%) |
FIGURE 13 Country-Level Contribution Heat Map, 2025 |
FIGURE 14 Competitive Landscape – Estimated Share Bands, 2026 |
FIGURE 15 Strategic Positioning Quadrant of Leading Providers

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
Therapy Type	Gene Therapy, Cell Therapy, Tissue-Engineered Products	Cell Therapy	Gene Therapy
Service Type	Process Development, cGMP Manufacturing, Analytical & Testing, Fill-Finish, Regulatory & QA Support	cGMP Manufacturing	Regulatory & QA Support
Development Phase	Pre-Clinical, Phase I/II, Phase III, Commercial	Phase III	Pre-Clinical
Vector Type	AAV, Lentiviral, Adenoviral, Retroviral, Non-Viral / Other	AAV	Lentiviral
Cell Source	Autologous, Allogeneic	Autologous	Allogeneic
Geography	North America, Europe, Asia-Pacific, Middle East & Africa, South America	North America	Asia-Pacific

Market Segmentation Overview

By Therapy Type

Sub-Segment	Key Trend
Gene Therapy	In-vivo rare-disease approvals drive long-tail vector demand
Cell Therapy	Approved CAR-T products lock in continuous patient-specific batches
Tissue-Engineered Products	Orthopaedic and dermal repair applications broaden slowly

Therapy-type demand is bifurcating. Approved autologous products generate steady, non-discretionary batch volume, while gene therapy programmes deliver lumpier but higher-value engagements tied to vector campaigns and long-term follow-up commitments.

By Service Type

Sub-Segment	Key Trend
Process Development	Cost-of-goods reduction mandates deepen sponsor engagement
cGMP Manufacturing	Commercial and pivotal supply anchors provider revenue
Analytical & Testing	Potency and identity assay requirements expand scope
Fill-Finish	Cryopreserved container-closure specialisation grows
Regulatory & QA Support	Multi-region filing complexity lifts advisory demand

Service mix is shifting upstream and downstream simultaneously. Sponsors want process development that lowers unit cost and regulatory support that survives multi-jurisdiction scrutiny, squeezing providers who offer only suite hours.

By Development Phase

Sub-Segment	Key Trend
Pre-Clinical	Widening IND funnel drives fastest incremental demand
Phase I/II	Broad pipeline sustains high engagement counts
Phase III	Validation lot requirements maximise revenue per programme
Commercial	Long-duration supply agreements stabilise utilisation

Phase distribution reveals provider strategy. Operators chasing pre-clinical volume build relationship pipelines; those prioritising Phase III and commercial work optimise for predictable suite loading and higher margins.

By Vector Type

Sub-Segment	Key Trend
AAV	Suspension platforms improve yield and lower per-dose cost
Lentiviral	Ex-vivo engineering demand grows with CAR-T expansion
Adenoviral	Oncolytic and immunisation programmes sustain baseline use
Retroviral	Legacy processes persist in approved products
Non-Viral / Other	Transposon and lipid nanoparticle routes gain IND share

Vector selection increasingly determines vendor shortlists. Providers with both AAV and lentiviral platform master files under one quality system win transfers that would otherwise fragment across suppliers.

By Cell Source

Sub-Segment	Key Trend
Autologous	Patient-specific scheduling and chain-of-identity dominate operations
Allogeneic	Donor-derived batches promise step-change unit economics

Cell source dictates facility design more than any other variable. Autologous work needs many small parallel suites with rigorous segregation; allogeneic work rewards fewer, larger bioreactor trains and conventional batch release.

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”